Differential expression of vasoactive intestinal peptide receptor 1 expression in inflammatory bowel disease.

Yukawa T, Oshitani N, Yamagami H, Watanabe K, Higuchi K, Arakawa T

International journal of molecular medicine1 Aug 2007Cited by 20 (Europe PMC)

PMID17611633DOI10.1111/j.1445-5994.2006.01278.xPepBankPUB-17611633

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

01HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
In intestinal samples from people with inflammatory bowel disease, the number of VIPR1-positive cells was higher in inflamed mucosa.
In plain wordsIn bowel tissue from people with inflammatory bowel disease, there were more cells carrying the VIP receptor VIPR1 in inflamed mucosa.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVIPR1-positive cells in inflammatory mucosa
Study
n = 35
Surgically resected intestinal samples
Outcome group
Inflammation markers · Gastrointestinal
Source sentences
Summary
Results showed that the number of VIPR1-positive cells was significantly increased in the inflammatory mucosa.
1 context sentence(design, population, supporting numbers)
Summary · context
We determined the location of VIP receptor 1 (VIPR1) immunohistologically in surgically resected intestinal samples from 10 controls, 15 patients with ulcerative colitis, and 10 patients with Crohn's disease.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1761163301
02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
The proportion of VIPR1-positive cells among CD3-positive cells was higher in the lamina propria in ulcerative colitis than in Crohn's disease and controls.
In plain wordsAmong T cells in the gut lining, a higher share carried the VIP receptor VIPR1 in ulcerative colitis than in Crohn's disease or controls.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVIPR1-positive proportion among CD3-positive cells
Study
n = 35
Surgically resected intestinal samples
Comparator
Crohn's disease and controls
Outcome group
Inflammation markers · Gastrointestinal
Source sentences
Summary
The proportion of VIPR1-positive cells among CD3-positive cells was significantly higher in the lamina propria of patients with ulcerative colitis than in those with Crohn's disease and the controls.
1 context sentence(design, population, supporting numbers)
Summary · context
We determined the location of VIP receptor 1 (VIPR1) immunohistologically in surgically resected intestinal samples from 10 controls, 15 patients with ulcerative colitis, and 10 patients with Crohn's disease.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1761163302
03HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
The proportion of VIPR1-positive cells among CD68-positive cells was higher in ulcerative colitis and Crohn's disease than in controls.
In plain wordsAmong CD68-positive immune cells, a higher share carried the VIP receptor VIPR1 in ulcerative colitis and Crohn's disease than in controls.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseVIPR1-positive proportion among CD68-positive cells
Study
n = 35
Surgically resected intestinal samples
Comparator
Controls
Outcome group
Inflammation markers · Gastrointestinal
Source sentences
Summary
The proportion of VIPR1-positive cells among CD68-positive cells was significantly higher in patients with ulcerative colitis and Crohn's disease than in the controls.
1 context sentence(design, population, supporting numbers)
Summary · context
We determined the location of VIP receptor 1 (VIPR1) immunohistologically in surgically resected intestinal samples from 10 controls, 15 patients with ulcerative colitis, and 10 patients with Crohn's disease.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1761163303
04HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
In ulcerative colitis, the numbers of VIPR1-positive and IL-4-positive cells were correlated.
In plain wordsIn ulcerative colitis tissue, cell counts for the VIP receptor VIPR1 and for IL-4 rose and fell together.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIPR1 and IL-4 cell counts correlation in ulcerative colitis
Study
n = 15
Surgically resected intestinal samples
Outcome group
Inflammation markers · Gastrointestinal
Source sentences
Summary
A correlation between the numbers of VIPR1- and IL-4-positive cells was found in patients with ulcerative colitis, and between the numbers of VIPR1- and TNF-alpha-positive cells in patients with Crohn's disease.
1 context sentence(design, population, supporting numbers)
Summary · context
We determined the location of VIP receptor 1 (VIPR1) immunohistologically in surgically resected intestinal samples from 10 controls, 15 patients with ulcerative colitis, and 10 patients with Crohn's disease.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1761163304
05HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
In Crohn's disease, the numbers of VIPR1-positive and TNF-alpha-positive cells were correlated.
In plain wordsIn Crohn's disease tissue, cell counts for the VIP receptor VIPR1 and for TNF-alpha rose and fell together.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIPR1 and TNF-alpha cell counts correlation in Crohn's disease
Study
n = 10
Surgically resected intestinal samples
Outcome group
Inflammation markers · Gastrointestinal
Source sentences
Summary
and between the numbers of VIPR1- and TNF-alpha-positive cells in patients with Crohn's disease.
1 context sentence(design, population, supporting numbers)
Summary · context
We determined the location of VIP receptor 1 (VIPR1) immunohistologically in surgically resected intestinal samples from 10 controls, 15 patients with ulcerative colitis, and 10 patients with Crohn's disease.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1761163305
06HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyMechanism
In intestinal samples from people with inflammatory bowel disease, VIPR1 was expressed in CD3-, CD19- and CD68-positive cells.
In plain wordsIn bowel tissue from people with inflammatory bowel disease, the VIP receptor VIPR1 was found in cells marked CD3, CD19 and CD68.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableCell types expressing VIPR1 in intestinal mucosa
Study
n: not reported in source
Surgically resected intestinal samples
Outcome group
Inflammation markers · Gastrointestinal
Source sentences
Summary
VIPR1 was expressed in CD3-, CD19-, and CD68-positive cells.
1 context sentence(design, population, supporting numbers)
Summary · context
We determined the location of VIP receptor 1 (VIPR1) immunohistologically in surgically resected intestinal samples from 10 controls, 15 patients with ulcerative colitis, and 10 patients with Crohn's disease.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1761163306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.